The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.
Helena Alexandra Yu
No relevant relationships to disclose
Camelia S. Sima
No relevant relationships to disclose
Alexander Edward Dela Cruz Drilon
No relevant relationships to disclose
Anna M. Varghese
No relevant relationships to disclose
Maria Catherine Pietanza
No relevant relationships to disclose
Christopher G. Azzoli
No relevant relationships to disclose
Naiyer A. Rizvi
No relevant relationships to disclose
Lee M. Krug
Consultant or Advisory Role - Genentech
Mark G. Kris
No relevant relationships to disclose
Vincent A. Miller
Employment or Leadership Position - Foundation Medicine
Consultant or Advisory Role - Astellas Pharma; Boehringer Ingelheim; Clovis Oncology; Genentech
Stock Ownership - Foundation Medicine
Gregory J. Riely
Consultant or Advisory Role - Abbott Laboratories; ARIAD; Chugai Pharma; Daiichi Sankyo; Tragara
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Infinity; Merck; Pfizer